Home > Publications database > Immune checkpoint inhibition alters patterns of failure in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy. > print

001     305607
005     20251109023627.0
024 7 _ |a 10.1007/s00432-025-06355-y
|2 doi
024 7 _ |a pmid:41175229
|2 pmid
024 7 _ |a 0301-1585
|2 ISSN
024 7 _ |a 0084-5353
|2 ISSN
024 7 _ |a 0171-5216
|2 ISSN
024 7 _ |a 1432-1335
|2 ISSN
024 7 _ |a altmetric:183676870
|2 altmetric
037 _ _ |a DKFZ-2025-02257
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Taugner, Julian
|0 0000-0003-1473-1202
|b 0
245 _ _ |a Immune checkpoint inhibition alters patterns of failure in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy.
260 _ _ |a Heidelberg
|c 2025
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1762172898_899166
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a We compared failure patterns in patients with inoperable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT) alone versus CRT combined with sequential and/or concurrent immune checkpoint inhibitors (CRT-IO).Retrospective real-world data from 221 patients across two German tertiary cancer centers were analyzed. Of these, 74 received CRT-IO, including sequential durvalumab (85%) and concurrent/sequential nivolumab (15%), while 148 received CRT alone. First failure site and time to failure were compared.Between 2012 and 2022, all patients received thoracic radiotherapy (≥ 60 Gy) and at least two cycles of platinum-based chemotherapy. Induction chemotherapy was administered in 36%, and induction chemo-immunotherapy in 2%. Median follow-up was 51.7 months (95% CI 47.0-56.4). Median overall survival (OS) for the entire cohort was 37.1 months (95% CI 26.0-48.2), with OS in the CRT-IO group not reached vs. 27.1 months (95% CI 18.5-25.7) in the CRT group (p < 0.001). Median progression-free survival (PFS) was 22.8 months (95% CI 6.4-39.1) for CRT-IO versus. 9.9 months (95% CI 7.0-12.8) for CRT (p = 0.001, see Fig. 1). Failure patterns differed significantly. CRT-IO patients had lower loco-regional progression (LRP) rates (9.5% vs. 21.8%, p = 0.023) and were more frequently alive without progression (45.9% vs. 16.3%, p < 0.001). Brain metastasis (BM) as the first failure, multifocal progression (MFP) and isolated extracranial distant metastasis (ecDM) rates were comparable between the CRT and CRT-IO subgroup. Women had a higher risk of isolated BM (17.3% vs. 6.8%, p = 0.016), whereas squamous cell carcinoma (SCC) patients had higher LRP rates (25.3% vs. 13.0%, p = 0.016). Median post-progression survival (PPS) was 19.4 months (95% CI 16.8-22.0) for CRT-IO and 9.5 months (95% CI 5.8-13.1) for CRT (p = 0.207). PPS was longer after BM (19.9 months) vs. LRP (8.5 months, p = 0.076) and significantly better in women (20.7 vs. 8.9 months, p = 0.012) and adenocarcinoma/non-otherwise-specified-carcinoma (AC/NOS) vs. SCC (p < 0.001).CRT-IO significantly improves OS, PFS, and LRP control compared to CRT alone. Failure patterns and survival disparities by histology and gender suggest tailored surveillance and treatment strategies are needed. Further studies should optimize management of LRP and long-term outcomes in CRT-IO-treated patients.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Chemoradiotherapy
|2 Other
650 _ 7 |a Immunotherapy
|2 Other
650 _ 7 |a Lung cancer
|2 Other
650 _ 7 |a NSCLC
|2 Other
650 _ 7 |a Patterns-of-failure
|2 Other
650 _ 7 |a Immune Checkpoint Inhibitors
|2 NLM Chemicals
650 _ 7 |a Nivolumab
|0 31YO63LBSN
|2 NLM Chemicals
650 _ 7 |a durvalumab
|0 28X28X9OKV
|2 NLM Chemicals
650 _ 7 |a Antibodies, Monoclonal
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Carcinoma, Non-Small-Cell Lung: therapy
|2 MeSH
650 _ 2 |a Carcinoma, Non-Small-Cell Lung: pathology
|2 MeSH
650 _ 2 |a Carcinoma, Non-Small-Cell Lung: drug therapy
|2 MeSH
650 _ 2 |a Carcinoma, Non-Small-Cell Lung: mortality
|2 MeSH
650 _ 2 |a Carcinoma, Non-Small-Cell Lung: immunology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Immune Checkpoint Inhibitors: therapeutic use
|2 MeSH
650 _ 2 |a Immune Checkpoint Inhibitors: administration & dosage
|2 MeSH
650 _ 2 |a Lung Neoplasms: pathology
|2 MeSH
650 _ 2 |a Lung Neoplasms: therapy
|2 MeSH
650 _ 2 |a Lung Neoplasms: drug therapy
|2 MeSH
650 _ 2 |a Lung Neoplasms: mortality
|2 MeSH
650 _ 2 |a Lung Neoplasms: immunology
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Chemoradiotherapy: methods
|2 MeSH
650 _ 2 |a Neoplasm Staging
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Treatment Failure
|2 MeSH
650 _ 2 |a Nivolumab: administration & dosage
|2 MeSH
650 _ 2 |a Antineoplastic Combined Chemotherapy Protocols: therapeutic use
|2 MeSH
650 _ 2 |a Antibodies, Monoclonal
|2 MeSH
700 1 _ |a Stamer, Silja
|b 1
700 1 _ |a Hofstetter, Kerstin
|b 2
700 1 _ |a Eze, Chukwuka
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Käsmann, Lukas
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Clasen, Kerstin
|b 5
700 1 _ |a Hartig, Philipp
|b 6
700 1 _ |a Spengler, Werner
|b 7
700 1 _ |a Groß, Thorben
|b 8
700 1 _ |a Manapov, Farkhad
|b 9
700 1 _ |a Belka, Claus
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Niyazi, Maximilian
|0 P:(DE-HGF)0
|b 11
773 _ _ |a 10.1007/s00432-025-06355-y
|g Vol. 151, no. 12, p. 313
|0 PERI:(DE-600)1459285-X
|n 12
|p 313
|t Journal of cancer research and clinical oncology
|v 151
|y 2025
|x 0301-1585
909 C O |o oai:inrepo02.dkfz.de:305607
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-20
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-20
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-20
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-20
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-20
920 1 _ |0 I:(DE-He78)MU01-20160331
|k MU01
|l DKTK Koordinierungsstelle München
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)MU01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21